Skip to main content
Premium Trial:

Request an Annual Quote

Swiss Proteomics Firm Biognosys Raises $3M in Series A

NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys has raised CHF2.7 million ($3 million) in a Series A round, it announced on Monday.

Participants in the round include Hellmut Kirchner, the co-founder of venture fund Techno Venture Management; Redalpine Capital I, which led Biognosys' seed funding in 2009; ZKB, the venture arm of Cantonal Bank of Zurich; Syngenta Ventures; and private investors.

"With the completion of this Series A round, we are well capitalized to bring Biognosys to the next phase of growth," Oliver Rinner, the company's CEO, said in a statement. He did not provide further details about the use of the funds.

In connection with the funding, Biognosys also announced additions to its board including Kirchner, Ignacio Martinez, a principal in Syngenta Ventures, and Harry Welten, CFO of Cytos Biotechnology.

Biognosys was spun out of the Swiss Federal Institute of Technology in 2008 and provides targeted mass spectrometry-based services to companies operating in the diagnostics, pharma, healthcare, biotechnology, and agricultural spaces. Customers include Novartis, Pfizer, Integrated Diagnostics, and Philips, according to its website.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.